There is knowledge gap between the West and sub-Saharan Africa on dementia biomarkers. To bridge this, the Alzheimer's Disease Biomarker-Nigeria (ADIBIO-N) cohort was established.
Objective
This study reported baseline data for Alzheimer's disease (AD) blood-based biomarkers in ADIBIO-N and the association of these biomarkers with measures of cognition. We also reported demographic differences in plasma biomarkers.
Methods
Three hundred older adults were recruited. At baseline, blood samples were analyzed for amyloid-β 42/40 (Aβ42/40), phosphorylated tau 181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Cognition was measured at baseline and two follow-up visits.
Results
Results showed significant sex differences for NfL. Significant relationships were found between GFAP, education, and composite cognition. The same is true for NfL and composite cognition. Significant negative associations were found between GFAP, memory, and language. A significant negative relationship was found between NfL and visuospatial cognition. Equally, significant positive associations were found for GFAP and age (0.26), and Aβ42/40 ratio and age (0.17) while adjusting for sex and education. Using the area under the curve for receiver operating characteristics, GFAP demonstrated good discriminative ability (0.70) for classifying cognitively unimpaired from non-amnestic mild cognitive impairment. Finally, a reference value was established for all the biomarkers across three diagnostic categories.
Conclusions
We found a baseline significant association of GFAP and NfL with composite and domain-specific cognitions, respectively, but not on amyloid and p-tau, contrary to findings from outside Africa that have repeatedly shown an association of amyloid and p-tau with cognition.
Alzheimer’s Disease International. From plan to impact VII: Dementia at crossroads. London: Alzheimer's Disease International, 2024.
3.
GuerchetMMaystonRLloyd-SherlockP, et al.Dementia in sub-Saharan Africa: Challenges and opportunities. London: Alzheimer’s Disease International, 2017.
4.
AdeloyeDAutaAEzejimoforM, et al.Prevalence of dementia in Nigeria: a systematic review of the evidence. J Glob Health Rep2019; 3: e2019014.
5.
UcheagwuVGiordaniB. Prevalence and patterns of cognitive impairment in a sample of community-dwelling older people in Nigeria. JAR Life2023; 12: 85–92.
6.
JackCRJrBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
SanchezEWilkinsonTCoughlanG, et al.Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario neurodegenerative disease research initiative. Alzheimers Dement2023; 20: 1753–1770.
9.
FonsecaLMBeeriMSHawksZW, et al.ATN Plasma biomarkers and digital cognitive performance in adults with type 1 diabetes: data from the GluCog study. Alzheimers Dement (Amst)2024; 16: e70029.
10.
LorenzLMCZhangMTesiN, et al.The association between levels of plasma biomarkers and cognitive performance in the oldest old. Alzheimers Dement2023; 19: e078964.
11.
AskenBMWangWMcFarlandK, et al.Plasma Alzheimer’s biomarkers and brain amyloid in Hispanic and non-Hispanic older adults. Alzheimers Dement2024; 20: 437–446.
12.
SchwinneMAlonsoARobertsBR, et al.The association of Alzheimer's disease-related blood-based biomarkers with cognitive screening test performance in the Congolese population in Kinshasa. J Alzheimers Dis2024; 97: 1353–1363.
13.
IkangaJJeanKMedinaP, et al.Preliminary reference values for Alzheimer’s disease plasma biomarkers in Congolese individuals with and without dementia. Front Aging Neurosci2024; 16: 1477047.
14.
JakAJBondiMWDelano-WoodL, et al.Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry2009; 17: 368–375.
15.
WeintraubSBesserLDodgeHH, et al.Version 3 of the Alzheimer's disease Centers’ neuropsychological test battery in the uniform data set (UDS). Alzheimer Dis Assoc Disord2018; 32: 10–17.
16.
IvanovaISalmonDPGollanTH. The multilingual naming test in Alzheimer’s disease: clues to the origin of naming impairments. J Int Neuropsychol Soc2013; 19: 272–283.
17.
UcheagwuVOdiloraCUgokwe-JosephR, et al.Factor structure and internal consistency of the national Alzheimer coordinating center’s uniform data set version 3 neuropsychological test battery (UDSNB 3.0): the Nigeria sample. Alzheimer Dis Assoc Disord2024; 38: 265–270.
18.
JackCRJrAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement2024; 20: 5143–5169.
19.
KeshavanAPanneeJKarikariTK, et al.Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain2021; 2: 434–449.
20.
GottesmanRFSchneiderALCZhouY, et al.The ARIC-PET amyloid imaging study. Neurology2016; 87: 473–480.
21.
CavedoEChiesaPAHouotM, et al.Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer’s disease in a monocenter cohort of cognitively normal older adults with subjective memory complaints. Alzheimers Dementia2018; 14: 1204–1215.
22.
JackCRWisteHJWeigandSD, et al.Age, sex, andAPOEε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol2015; 72: 511.
23.
RosanoCKarikariTKCvejkusR, et al.Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: the Tobago Health Study. Alzheimers Dement2024; 12: e12460.
24.
VogelgsangJHansenNStarkM, et al.Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease. Alzheimers Dement2024; 20: 5132–5142.
25.
OsuntokunBOOgunniyiAAkangEEU, et al.βA4-amyloid in the brains of non-demented Nigerian Africans. Lancet1994; 343: 56.
26.
TrelleANYoungCBVosslerH, et al.Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimers Dement2025; 21: e14442.
27.
MielkeMMHagenCEXuJ, et al.Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement2018; 14: 989–997.
28.
WooMSTherriaultJJonaitisEM, et al.Identification of late-stage tau accumulation using plasma phospho-tau217. EBioMedicine2024; 109: 105413.
29.
TsikniaAAEdlandSDSundermannEE, et al.Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry2022; 27: 4314–4322.
30.
TuckerMKramerJHCasalettoKB, et al.Sex differences in plasma phosphorylated-tau181 vary between older adults with and without mild cognitive impairment. Alzheimers Dement2023; 19: e063479.
31.
GonzalezMCAshtonNJGomesBF, et al.Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol2022; 1: 32–37.
32.
GiacomucciGMazzeoSCrucittiC, et al.Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's disease pathology in subjective cognitive decline and mild cognitive impairment. J Neurol Sci2023; 453: 120805.
33.
CanoACapdevilaMPuertaR, et al.Clinical value of plasma pTau181 to predict Alzheimer’s disease pathology in a large real-world cohort of a memory clinic. EBioMedicine2024; 108: 105345.
34.
OecklPHalbgebauerSAnderl-StraubS, et al.Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis2019; 67: 481–488.
35.
IngannatoABagnoliSMazzeoS, et al.Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Front Endocrinol2024; 15: 1375302.
36.
ChatterjeePPedriniSAshtonNJ, et al.Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement2022; 18: 1141–1154.
37.
KumarAFontanaICNordbergA. Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer’s disease. J Neurochem2023; 164: 309–324.
38.
BettcherBMOlsonKECarlsonNE, et al.Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer’s disease. Neurobiol Aging2021; 103: 68–77.
39.
AllamanIGavilletMBelangerM, et al.Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci2010; 30: 3326–3338.
40.
NarayanPHolmstromKMKimDH, et al.Rare individual amyloid-beta oligomers act on astrocytes to initiate neuronal damage. Biochemistry2014; 53: 2442–2453.
41.
TongHZhangXMengX, et al.Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. Int J Biochem Cell Biol2017; 85: 75–84.
42.
WyssenbachAQuintelaTLlaveroF, et al.Amyloid beta-induced astrogliosis is mediated by beta1-integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell2016; 15: 1140–1152.
Serrano-PozoAMielkeMLGomez-IslaT, et al.Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol2011; 179: 1373–1384.
45.
PereiraJBJanelidzeSSmithR, et al.Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain2021; 144: 3505–3516.
46.
BellaverBFerrari-SouzaJPUglione da RosL, et al.Astrocyte biomarkers in Alzheimer's disease: a systematic review and meta-analysis. Neurology2021; 96: e2944–e2955.
47.
CicognolaCJanelidzeSHertzeJ, et al.Plasma glial fibrillary acidic protein detects Alzheimer's pathology and predicts future conversion to Alzheimer's dementia in patients with mild cognitive impairment. Alzheimers Res Ther2021; 13: 68.
48.
OecklPAnderl-StraubSVon ArnimCAF, et al.Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry2022; 93: 659–667.
MielkeMMSyrjanenJABlennowK, et al.Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimers Dement2019; 15: 1437–1447.
51.
BridelCvan WieringenWNZetterbergH, et al.Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol2019; 76: 1035–1048.
52.
LinYSLeeWJWangSJ, et al.Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer's or Parkinson's disease. Sci Rep2018; 8: 17368.
53.
MielkeMMSyrjanenJABlennowK, et al.Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology2019; 93: e252–e260.
54.
MattssonNCullenNCAndreassonU, et al.Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer's disease. JAMA Neurol2019; 76: 791–799.
55.
ChatterjeePGoozeeKSohrabiHR, et al.Association of plasma neurofilament light chain with neocortical amyloid-beta load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis2018; 63: 479–487.
56.
GaoYSuDXueZ, et al.Association between serum neurofilament light chain and cognitive performance among older adults in the United States: a cross-sectional study. Neurol Ther2023; 12: 2147–2160.
57.
HeLMorleyJEAggarwalG, et al.Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Sci Rep2021; 11: 13394.
